Pfizer (STU:PFE) ROCE %

: -7.51% (As of Dec. 2023)

View and export this data going back to 1951. Start your Free Trial

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Pfizer's annualized ROCE % for the quarter that ended in Dec. 2023 was -7.51%.

Pfizer ROCE % Historical Data

The historical data trend for Pfizer's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pfizer Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

10.12

6.26

19.85

25.22

1.93

Pfizer Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															14.01	16.69	6.41	-5.80	-7.51

Pfizer ROCE % Calculation

Pfizer's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	2995.839	/	( ( (186161.52 - 39778.272)	+	(207701.417 - 43827.098) )	/ 2 )
	=	2995.839	/	( (146383.248	+	163874.319)	/ 2 )
	=	2995.839	/	155128.7835
	=	1.93 %

Pfizer's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-12621.588	/	( ( (201474.677 - 29174.432)	+	(207701.417 - 43827.098) )	/ 2 )
	=	-12621.588	/	( ( 172300.245	+	163874.319 )	/ 2 )
	=	-12621.588	/	168087.282
	=	-7.51 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Pfizer (STU:PFE) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Pfizer ROCE % Related Terms

Thank you for viewing the detailed overview of Pfizer's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Pfizer (STU:PFE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pfizer Inc (STU:PFE) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

PFE:USA PFE:Peru PFE:Mexico PFE_KZ:Kazakhstan 1PFE:Italy PFEd:UK 0Q1N:UK PFE:Germany PFE:Chile PFE:Canada PFIZ34:Brazil PFE:Austria PFE:Argentina

Address

66 Hudson Boulevard East, New York, NY, USA, 10001-2192

Website

https://www.pfizer.com

Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.